We are live on ! Find out more
UOC

UBS O'Connor Portfolio holdings

AUM $3.76B
1-Year Est. Return 62.41%
This Fund
S&P 500
This Quarter Est. Return
+7.76%
1 Year Est. Return
+62.41%
3 Year Est. Return
+179.84%
5 Year Est. Return
+371.69%
10 Year Est. Return
+1,534.25%
AUM
$4.75B
AUM Growth
+$529M
Cap. Flow
+$146M
Cap. Flow %
3.08%
Top 10 Hldgs %
47.97%
Holding
745
New
128
Increased
150
Reduced
259
Closed
162
Avg Time Held Equity + Options
3.8 quarters
Top 10 Avg Time Held Equity + Options
1.1 quarters
Top 20 Avg Time Held Equity + Options
1.1 quarters
Avg Time Held Equity only
3.9 quarters
Top 10 Avg Time Held Equity only
1.1 quarters
Top 20 Avg Time Held Equity only
1.1 quarters

Top Buys

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$253M
2
PDCE
PDC Energy, Inc.
PDCE
+$210M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$206M
4
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
+$135M
5
LSI
Life Storage, Inc.
LSI
+$87.5M

Top Sells

Rank Stock Value
1
FHN icon
First Horizon
FHN
+$179M
2
AQUA
Evoqua Water Technologies Corp. Common Stock
AQUA
+$146M
3
PRVB
Provention Bio, Inc. Common Stock
PRVB
+$70.5M
4
TSEM icon
Tower Semiconductor
TSEM
+$50.8M
5
XM
Qualtrics International Inc. Class A Common Stock
XM
+$45.3M

Sector Composition

Rank Sector Weight
1 Healthcare 32.35%
2 Technology 15.68%
3 Financials 11.99%
4 Miscellaneous 10.5%
5 Real Estate 8.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
MRVL icon
376
Marvell Technology
MRVL
$242B
$897K 0.02%
+15,000
New +$729K
2023 Q2
0 quarters
OSI icon
377
DELISTED
Osiris Acquisition Corp.
OSI
$877K 0.02%
80,570
-1,816
-2% -$18.1K
2021 Q3
7 quarters
XFOR icon
378
X4 Pharmaceuticals
XFOR
$258M
$873K 0.02%
+15,000
New +$771K
2023 Q2
0 quarters
INBX icon
379
DELISTED
Inhibrx, Inc. Common Stock
INBX
$868K 0.02%
33,448
+1,648
+5% +$38.5K
2022 Q2
4 quarters
INZY icon
380
DELISTED
Inozyme Pharma
INZY
$865K 0.02%
155,305
+7,651
+5% +$45.2K
2022 Q2
4 quarters
AMLX icon
381
Amylyx Pharmaceuticals
AMLX
$3.37B
$841K 0.02%
+39,000
New +$1.05M
2023 Q2
0 quarters
MORF icon
382
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$839K 0.02%
14,635
-15,917
-52% -$831K
2022 Q1
5 quarters
ATVI
383
CALL
DELISTED
Activision Blizzard
ATVI
$825K 0.02%
506,300
-27,400
-5% -$2.22M
2023 Q1
1 quarter
RH icon
384
RH
RH
$2.19B
$824K 0.02%
+2,500
New +$653K
2023 Q2
0 quarters
BHAC icon
385
DELISTED
Focus Impact BH3 Acquisition Company Class A Common Stock
BHAC
$819K 0.02%
78,575
-2,557
-3% -$26.4K
2021 Q4
6 quarters
AMC icon
386
PUT
AMC Entertainment Holdings
AMC
$2.73B
$811K 0.02%
+35,000
New +$1.73M
2023 Q2
0 quarters
CRC icon
387
California Resources
CRC
$4.82B
$770K 0.02%
17,004
-955
-5% -$38.8K
2020 Q4
10 quarters
DBTX
388
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
$767K 0.02%
199,200
+9,814
+5% +$36K
2022 Q2
4 quarters
QTRX icon
389
Quanterix
QTRX
$149M
$767K 0.02%
+34,000
New +$606K
2023 Q2
0 quarters
IRON icon
390
Disc Medicine
IRON
$2.17B
$760K 0.02%
17,121
-28,629
-63% -$1.02M
2023 Q1
1 quarter
ACRS icon
391
Aclaris Therapeutics
ACRS
$511M
$757K 0.02%
73,014
-10,664
-13% -$96.5K
2022 Q1
5 quarters
PHM icon
392
Pultegroup
PHM
$21.3B
$733K 0.02%
9,441
-48,152
-84% -$3.26M
2022 Q4
2 quarters
DHI icon
393
D.R. Horton
DHI
$37.9B
$728K 0.02%
+5,985
New +$654K
2023 Q2
0 quarters
ZTO icon
394
ZTO Express
ZTO
$15.5B
$722K 0.02%
28,800
-53,558
-65% -$1.47M
2021 Q2
8 quarters
SDGR icon
395
Schrodinger
SDGR
$1.94B
$709K 0.01%
14,200
-3,881
-21% -$131K
2022 Q1
5 quarters
XRX icon
396
PUT
Xerox
XRX
$373M
$709K 0.01%
248,800
– –
2021 Q2
8 quarters
DTIL icon
397
Precision BioSciences
DTIL
$168M
$704K 0.01%
44,610
+14,082
+46% +$322K
2022 Q2
4 quarters
GLUE icon
398
Monte Rosa Therapeutics
GLUE
$844M
$688K 0.01%
100,478
+4,950
+5% +$32K
2022 Q1
5 quarters
ITOS icon
399
DELISTED
iTeos Therapeutics
ITOS
$685K 0.01%
51,764
-17,536
-25% -$250K
2022 Q1
5 quarters
VKTX icon
400
Viking Therapeutics
VKTX
$3.39B
$679K 0.01%
41,905
-23,703
-36% -$497K
2022 Q3
3 quarters
14 15
16
17 18

Similar funds

FNBT
FineMark National Bank & Trust Fort Myers, Florida $3.2B AUM 18.28% 1-Year Est. Return
ACI
Alpha Cubed Investments Irvine, California $2.92B AUM 31.27% 1-Year Est. Return
RC
RGM Capital Naples, Florida $2.06B AUM 8.49% 1-Year Est. Return
A
AlphaQuest New York $1.79B AUM 10.61% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return
CB
Cadence Bank Tupelo, Mississippi $1.71B AUM 16.17% 1-Year Est. Return
JCM
Janney Capital Management Pittsburgh, Pennsylvania $1.59B AUM 23.25% 1-Year Est. Return
MPM
Meritage Portfolio Management Overland Park, Kansas $1.51B AUM 26.61% 1-Year Est. Return

UBS O'Connor's Q2 2023 Portfolio in Review

As of Q2 2023, UBS O'Connor held 745 positions worth $4.75B, up 13% from $4.22B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

UBS O'Connor deployed $146M of net new capital in Q2 2023, opening 128 new positions and adding to 150 existing holdings. Its largest new stake was PDC Energy, Inc.: 3,101,445 shares worth $221M.

By sector, the portfolio is most concentrated in Healthcare at 32% of assets, up from 21% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was Tower Semiconductor, an estimated $50.8M trimmed.

  • UBS O'Connor's largest Q2 2023 buy was PDC Energy, Inc.: 3,101,445 shares worth $221M.
  • UBS O'Connor added most to Seagen Inc. Common Stock in Q2 2023, an estimated $253M increase.
  • UBS O'Connor's biggest Q2 2023 reduction was Tower Semiconductor, cutting an estimated $50.8M.
  • UBS O'Connor fully exited First Horizon in Q2 2023, selling an estimated $179M.
  • UBS O'Connor's ten largest holdings make up 48% of its $4.75B portfolio in Q2 2023.
  • UBS O'Connor opened 128 new positions and closed 162 in Q2 2023.
  • UBS O'Connor's portfolio value rose 13% quarter-over-quarter to $4.75B.

Based on UBS O'Connor's 13F filing for Q2 2023, filed 14 Aug 2023.